Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Autoinjectors for Plaque Psoriasis
NCT01636687Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in plaque psoriasis (3 arms), sponsored by Novartis. Primary endpoints: Psoriasis Area and Severity Index 75 Response at 12 weeks and Investigator's Global Assessment Mod 2011 0 or 1 Response at 12 weeks. Started Oct 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01636687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636687.